Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943635 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL6178113 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL6180704 | 1.00 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29923644 | 0.91 | CRBN (0.83) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL19359391 | 0.91 | CRBN (0.83) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23292786 | 0.86 | CRBN (0.76) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL19359372 | 0.84 | CRBN (0.73) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL5435284 | 0.84 | CRBN (0.72) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29644513 | 0.84 | CRBN (0.72) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25834145 | 0.84 | CRBN (0.72) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | claimed |
| WO-2023177451-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | EnhancedBio Inc. (KR) | 2023-09-21 | — | — | WO | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | claimed |
| JP-4695259-B2 | — | — | 2011-06-08 | — | — | JP | claimed |
| CN-100390163-C | 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORP (US) | 2008-05-28 | — | — | CN | claimed |
| EP-1064277-B1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | CELGENE CORP (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1357120-A1 | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORPORATION (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2003-02-06 | — | — | US | claimed |
| US-6403613-B1 | ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) | CELGENE CORPORATION | 2002-06-11 | — | — | US | claimed |
| CN-1337959-A | 2- (2, 6-dioxopiperidin-3-yl) -isoindoline derivatives, process for their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORP (US) | 2002-02-27 | — | — | CN | claimed |
| US-6335349-B1 | AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2002-01-01 | — | — | US | claimed |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | MAN HON-WAH (US) | 2001-07-05 | — | — | US | claimed |
| EP-1064277-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | Gelgene Corporation (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999047512-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | COLGENE CORPORATION (US) | 1999-09-23 | — | — | WO | claimed |
| EP-4734989-A2 | SYNTHESIS AND IN VITRO CHARACTERIZATION OF PROTEOLYSIS TARGETING CHIMERAS (PROTACS) FOR DEGRADATION OF DNA METHYLTRANSFERASE 1 (DNMT1) | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-5955476-A | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| WO-1999046258-A1 | SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFα LEVELS | CELGENE CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5874448-A | DRUGS FOR REDUCING THE LEVEL OF TUMOR NECROSIS FACTOR, INCREASING ADENOSINE-3',5'CYCLIC MONOPHOSPHATE, INHIBITING PHOSPHODIESTERASE; TREATING BONE DISORDER, INFECTIONS, CANCER, IMMUNE DISEASE | CELGENE CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | TNF, IL1A, IL1B | CRBN 4134/4885DDB1 733/4885IKZF3 275/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | CRBN 1/4885DDB1 2979/4885IKZF3 80/4885 |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | TNF, IL1A, IL1B | CRBN 4134/4885DDB1 733/4885IKZF3 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.